The estimated Net Worth of Gregory C. Williams is at least $2.69 Millón dollars as of 25 February 2021. Mr. Williams owns over 50,000 units of Eloxx Pharmaceuticals Inc stock worth over $36 and over the last 10 years he sold ELOX stock worth over $0. In addition, he makes $2,690,850 as Chief Executive Officer y Director at Eloxx Pharmaceuticals Inc.
Gregory has made over 6 trades of the Eloxx Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of ELOX stock worth $30 on 25 February 2021.
The largest trade he's ever made was exercising 50,000 units of Eloxx Pharmaceuticals Inc stock on 25 February 2021 worth over $30. On average, Gregory trades about 4,333 units every 26 days since 2014. As of 25 February 2021 he still owns at least 59,989 units of Eloxx Pharmaceuticals Inc stock.
You can see the complete history of Mr. Williams stock trades at the bottom of the page.
Gregory Williams Ph.D. serves as Chief Executive Officer, Director of the Company. serves as Chief Executive Officer, Director of the Company.D. has been appointed as Chief Executive Officer, Director of the Company effective 2/29/2020. Dr. Greg Williams is an accomplished scientist and seasoned pharmaceutical executive with over 30 years of Pharmaceutical and Biotechnology experience and a solid track record of vision and achievement of business, medical, scientific and regulatory goals. His focus is on driving innovation to improve patient care by developing and commercializing new products to address unmet patient and health system needs. At the Medicines Company, Dr. Williams lead development and successful approval of the antihypertensive Cleviprex® after working on the orphan drug programs at NPS Pharmaceuticals. Most recently, while at Radius Health, Inc., Greg led the successful first cycle approval by the FDA of TYMLOS®. Greg brings established relationships with global health authority reviewers, having led the development and/or initial and expanded approvals of several global brands, as well as expertise across a wide range of therapeutic categories, molecule types, dosage forms and technologies. Dr. Williams holds a PhD in Biopharmaceutics from Rutgers University and an MBA from Cornell University.
As the Chief Executive Officer y Director of Eloxx Pharmaceuticals Inc, the total compensation of Gregory Williams at Eloxx Pharmaceuticals Inc is $2,690,850. There are no executives at Eloxx Pharmaceuticals Inc getting paid more.
Gregory Williams is 61, he's been the Chief Executive Officer y Director of Eloxx Pharmaceuticals Inc since 2020. There are 4 older and 6 younger executives at Eloxx Pharmaceuticals Inc. The oldest executive at Eloxx Pharmaceuticals Inc is Zafrira Avnur, 68, who is the Independent Director.
Gregory's mailing address filed with the SEC is C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv y Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: